Drug Pricing

For more than twenty years, the health insurance law (KVG) based assessment of effectiveness, appropriateness and cost-effectiveness in the healthcare system has largely not been implemented. The trigger for rethinking the situation is prompted by the Federal Office of Public Health's announcement that the potential savings in terms of drug prices, at CHF 168 million, were far greater than the previously estimated CHF 39 million. This is not really surprising, because there are clear deficiencies in pricing in the form of regulatory gaps.